GEEKS ON CALL HOLDINGS INCORPORATED (OTCBB: GOCH)
"Up 76.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/GOCH.php

Geeks On Call Holdings, Inc. was founded in 1999 and is a pioneer in the mobile, rapid-response on-site IT service concept. Under the trade names Geeks On Call®, 1-800-905-GEEK™, CallTheGeeks.com™ and Call The Geeks™, the Company's certified IT professionals service small businesses and residential customers through its national network of franchise and Company-owned locations. They provide computer privacy and security solutions, hardware and network installations and troubleshooting, as well as repairs, upgrades and consulting. Geeks On Call also co-markets through endorsed vendor relationships with other Franchisors, who offer GOC services to their franchisees as a value-added benefit. Over 250 independently owned and operated franchises have been granted, with new franchise and Corporate locations opening regularly.

GOCH News:

October 8 - Geeks On Call® Offers Online Telephone and Remote Technical Support at CallTheGeeks.com Starting at $19.95

Includes Initial Free Live Online Chat To Access Needs

Geeks On Call Holdings, Inc. (OTCBB: GOCH), a premier national provider of professional IT solutions to small business and residential customers under the trade names Geeks On Call®, 1-800-905-GEEK™, CallTheGeeks.com™ and Call The Geeks™, announced that CallTheGeeks.com is offering consumers telephone and online technical support via live chat and online diagnostics beginning at $19.95 for a single incident.

The services, which are offered in areas not currently covered by Geeks On Call on-site technicians, include computer troubleshooting and repair, performance optimization, software upgrades and support, operating system support, hardware diagnostics, and virus and spyware removal.

The friendly, industry-certified professionals of CallTheGeeks.com provide an initial free live chat to clarify and categorize computer issues, after which customers may opt for single incident resolution of their problem or one of three plans for unlimited phone, live chat, and/or remote computer support at reasonable flat-rate pricing.

Rich Artese, Executive Vice President and COO stated, "I am excited about our CallTheGeeks.com online service because it is a wonderful compliment to our premiere on-site technical service and support network and it brings us another step closer to providing coverage across a National footprint."

ABOUT CALL THE GEEKS™

Call The Geeks, a wholly owned subsidiary of Geeks On Call Holdings, Inc., is a telephone and remote support service provider that operates through the online portal CallTheGeeks.com. Call The Geeks trusted certified technicians are trained and tested using the rigorous screening process originally established for on-site employees. Hours of operation are Monday through Saturday, 8:00am to 12:00am, and Sunday 10:00am to 7:00pm, Eastern Standard Time.

MEDIVISOR INCORPORATED (OTC: MVSR)
"Up 52.94% on Wednesday"

Detailed Quote: www.otcpicks.com/quotes/MVSR.php

Medivisor, Inc. provides medical information to healthcare professionals, primarily physicians, through its Web sites, using inter-active, informational, and video and graphic presentations. It also focuses on offering Web site services to various industries seeking direct access to physicians, including providers of continuing medical education courses; sponsors of medical conferences and seminars; and pharmaceutical companies, using an online marketing format known as e-detailing. The company was founded in 2002 and is headquartered in Huntington Station, New York.

MVSR News:

October 7 - Medivisor, Inc. Featured in Profile at WallStreetResearch.org

Medivisor, Inc. (OTC: MVSR), developer of next-generation focus driven marketing tools, announced that it has been featured in a corporate profile posted at www.wallstreetresearch.org. WallStreet Research specializes in the microcap and smallcap arena, looking for emerging growth companies with strong management, unique proprietary technology, creative marketing, significant market potential, value, financial strength and outstanding long-term earnings growth.

"It is extremely encouraging that in spite of the current market climate, Medivisor's recent developments and outlook continue to be recognized by analysts. Not only has Medivisor, Inc. received a 'Speculative Buy Rating' at www.BeaconEquity.com, but it has also been profiled on the website www.wallstreetresearch.org," stated Dino Luzzi, CEO of Medivisor, Inc.

DECODE GENETICS INCORPORATED (NASDAQ: DCGN)
"Up 65.52% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/DCGN.php

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of diagnostics and drugs for common diseases. deCODE is a global leader in gene discovery — our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. Through its CLIA-registered laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2™ for type 2 diabetes; deCODE AF™ for atrial fibrillation and stroke; deCODE MI™ for heart attack; deCODE ProCa™ for prostate cancer; deCODE Glaucoma™ for a major type of glaucoma. deCODE is delivering on the promise of the new genetics.

DCGN News:

October 6 - deCODE Receives Nasdaq Deficiency Notice Relating to Market Value

deCODE Genetics Inc. (Nasdaq: DCGN) announced that on September 30, 2008 it received a notice from the Nasdaq Stock Market stating that for 10 consecutive trading days the market value of deCODE's common stock had been below $50 million, the minimum level required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Marketplace Rule 4450(b)(1)(A). The notice further stated that deCODE also does not comply with an alternative test set forth in Nasdaq Marketplace Rule 4450(b)(1)(B), which requires total assets and total revenue of $50 million each for the most recently completed fiscal year or two of the last three most recently completed fiscal years.

In accordance with Nasdaq Marketplace Rule 4450(e)(4), deCODE will be provided a period of 30 calendar days, or until October 30, 2008, to regain compliance. If at any time before October 30, 2008, the market value of deCODE's common stock is $50 million or more for a minimum of 10 consecutive business days, the Nasdaq staff will determine if deCODE complies with Marketplace Rule 4450(b)(1)(A).

If deCODE has not regained compliance by October 30, 2008, the Nasdaq staff will issue a letter notifying deCODE that its common stock will be delisted from The Nasdaq Global Market. At that time, deCODE may appeal the determination to a Nasdaq Listing Qualifications Panel. If deCODE cannot meet the requirements for continued listing on The Nasdaq Global Market, it will consider whether to apply to transfer its common stock to The Nasdaq Capital Market.

UNIVERSAL SYSTEMS INCORPORATED (OTC: UVSS)
"Up 40.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/UVSS.php

Universal Systems, Inc (USI) is a publicly traded holding company focused on providing economically and ecologically viable water and wastewater treatment solutions. USI offers FULL SERVICE turn-key water treatment services, specializing in "slop oil" and CBM (Coal Bed Methane) produced water. In 2007, USI obtained an exclusive worldwide licensing agreement to provide slop oil and processed wastewater treatment services to the oil industry. The company's mission is to become the leader in the development and delivery of cost effective slop oil and processed wastewater treatment. USI joined Powell Water Systems, Inc. (PWS) and Water Solutions, LLC (WS) to bring PWS' patented electrocoagulation technology to the oil industry, making large flow waste oil and water treatment efficient and cost effective.

UVSS News:

October 6 - Universal Systems and Atlas Monetary International Trust Complete Joint Venture Agreement

Universal Systems, Inc. (OTC: UVSS) announced that it has successfully signed a joint venture agreement with Atlas Monetary International Trust. The agreement encompasses several initiatives that are core to the Atlas mission. The first component of the agreement has been defined and awards to USI a contract for the design and production of a marine system for cleaning petroleum spills at the point of the spill. USI was selected by Atlas Trust for this joint venture based on the performance of its electro-coagulation systems and the environmental focus of the corporation. The patented technologies employed in these systems give them unrivaled volume flow performance and the ability to remove even the smallest traces of petroleum and other contaminants from seawater, potentially leaving it cleaner than it was before the spill. Discussions are underway that will award additional contracts to USI for environmental projects that are on the Atlas Trust strategic roadmap.

Atlas Trust will immediately purchase 8,000,000 shares of Universal common stock for a price of $25.00 per share, equaling $200,000,000 USD. This infusion of capital will enable Universal Systems to move forward with design of the marine-based electro-coagulation equipment and to take over the contract from Ocean Vacuum Corporation to produce ocean platforms to be used for clean up and recovery of oil spills and contaminated water. The contract calls for the design, manufacturing and assembly of approximately 16,000 ("Sixteen Thousand") units. The contract ceiling currently stands at $2.4 billion (USD); however this number will increase to cover the full projected cost of all systems when the final production cost is determined. Engineering will start immediately and a prototype system will be available for test within 9-months. A large portion of the assembly will take place in Puerto Rico while design, engineering and the building of the working prototype will take place in Baker City, Oregon. Universal has initiated negotiations for the purchase of several large blocks of real estate with existing buildings to accommodate its new cast of employees. Universal plans to move its head quarters there as well in order to consolidate operations and its other products. Production units will be leased to major oil companies and stored on their large oil tankers to act as a first line of defense for decontamination at the point of spill, should one occur. Had these systems been available at the time of the Valdez oil spill in Alaska the majority of the environmental effects felt through the release of millions of gallons of oil into the ocean could have been prevented.

Reflecting on the signing of the joint venture agreement with Atlas Trust, Mr. Kevin Chambers, CEO of Universal Systems, commented, "This agreement is the thread tying together the environmental technologies accumulated by USI over the past several years. These years have been spent in building a unique capability to make an impact on the state-of-the art in environmental cleanup. With the signing of this agreement, the long-standing vision is realized and USI stands fully empowered for execution. This is a momentous occasion for USI and for all who have wished for better ways to mitigate the damage of environmental mishaps on our oceans, beaches and marine life. And this is only the beginning."

PANACOS PHARMACEUTICALS INCORPORATED (NASD: PANC)
"Up 37.09% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/PANC.php

Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat Human Immunodeficiency Virus (HIV) and other human viral diseases. Its lead product candidate, bevirimat, under Phase 2 clinical trials, is a class of drug candidates that works by a novel mechanism of action called maturation inhibition. The company's discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. It also has research and development programs designed to generate second and third-generation maturation inhibition products; and a research and development program focused on an early step in the HIV virus life cycle, fusion of the HIV virus to human cells. The company was founded in 1999 and is headquartered in Watertown, Massachusetts.

PANC News:

October 7 - Panacos' Study 114 Supports the Company's New Tablet Formulation of Bevirimat

100mg Tablet Formulation will Move Forward in Development

Panacos Pharmaceuticals, Inc. (Nasdaq: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, announced its 100mg tablet formulation of bevirimat has shown very good bioavailability compared to the Company’s oral solution formulation of bevirimat. Bevirimat is the only novel-mechanism oral drug in late-stage development for HIV. This new tablet formulation will be used in the bevirimat extended-duration study, Study 205, and in the Phase 3 program, subject to positive results in the remainder of the Phase 2 program.

“Bevirimat has not been an easy product to formulate as a tablet. We have been successful in developing a 100mg bevirimat tablet that exceeds the bioavailability criteria we had identified to justify moving a tablet into future clinical development, particularly longer-term dosing in HIV patients. I would like to acknowledge the work our formulation team has done to achieve this important milestone,” stated Alan W. Dunton, MD, President and Chief Executive of Panacos. “Today’s news is significant for the Company and for the HIV patient population in need of new mechanism drugs.”

Study 114 was designed to evaluate the relative bioavailability of a 100mg tablet of bevirimat compared to the solution formulation (10% cyclodextrin) of bevirimat in 28 healthy volunteers. The volunteers received a single dose of bevirimat, either as 300mg of oral solution or three 100mg bevirimat tablets. Study 114 showed the bevirimat tablet formulation achieved a 68% AUC (area under the curve, a measure of total absorption of the drug) relative bioavailability compared to the solution. The Cmax (maximum plasma concentration) showed relative bioavailability of the tablet compared to the solution of 69%. These two measurements indicate the 100mg bevirimat tablet is well suited to study in HIV patients as well as to take forward into Study 205 and beyond.

Study 205, the design of which is not finalized, is expected to be a minimum 12-16 week study using this new 100mg bevirimat tablet with optimized background therapy in HIV patients whose virus does not have three key viral polymorphisms. Earlier in 2008, the Company identified polymorphisms within the viral Gag protein at positions 369, 370, and 371 as predictors of response to bevirimat. Since the initial announcement, the polymorphisms have been the subject of several presentations to HIV specialists around the world.

Panacos' Development Programs

Panacos' lead compound, bevirimat (PA-457), is the first in the new class of HIV drugs under development called maturation inhibitors, discovered by Company scientists and their academic collaborators. Bevirimat is designed to have potent activity against a broad range of HIV strains, and studies have shown bevirimat is a potent inhibitor of HIV isolates that are resistant to currently approved drugs. Panacos has completed 12 clinical studies with bevirimat in over 500 patients and healthy volunteers, showing significant reductions in viral load in HIV-infected patients and a promising safety profile. It is currently in Phase 2b clinical trials. The Company has completed a Phase 2b dose escalation study of bevirimat (Study 203) and determined the optimal dose range. The retrospective clinical data from Study 203 resulted in the discovery of the patient response predictors to bevirimat, which now has been confirmed in multiple laboratory analyses and a prospective study.

In addition to bevirimat, the Company has next-generation programs in HIV maturation inhibition and has selected a lead compound for preclinical development in its oral HIV fusion inhibitor program. The new understanding of the role of Gag polymorphisms in maturation inhibitor activity is unique to Panacos, and the Company is building a strong intellectual property position around its important discovery.

CHINA ORGANIC AGRICULTURE INCORPORATED (OTCBB: CNOA)
"Up 31.82% on Wednesday"

Detailed Quote: www.otcpicks.com/quotes/CNOA.php

China Organic Agriculture is an active trader of agricultural products in China. The Company's high-growth business plan is designed to enable it to capitalize effectively on China's burgeoning economy and expanding class of consumers with the ability to acquire upscale products. The Company has developed an extensive distribution network throughout many of China's major cities, including Beijing, Shanghai and Nanjing, and is positioned to leverage those networks to establish broad distribution of a number of agricultural, food and related premium products. The Company has experienced significant growth since its inception in 2002 and has implemented a number of strategic initiatives to expand sales and revenues.

CNOA News:

October 7 - China Organic Provides Preliminary Earnings Estimate for Third Quarter 2008

Strong Third Quarter Results Due to Record Sales from Ankang Subsidiary

China Organic Agriculture, Inc. (OTCBB: CNOA), a growth-driven agricultural products company, announced preliminary results for the third quarter 2008. The Company anticipates revenue between $34 million and $36 million, net income between $8 million and $9 million, and earnings per share of $0.14 to $0.16.

“I’m happy to report solid estimates for the third quarter 2008,” said Jinsong Li, Chief Executive Officer of China Organic. “Revenue of over $30 million in a single quarter will be a record for CNOA. With a majority of these sales coming from our Ankang subsidiary, we can be assured our business model’s focus on trading opportunities will provide strong growth for shareholders.”

As discussed in previous reports, this large jump in revenue for the quarter compared to the first two quarters of 2008 is largely due to the cyclical nature of rice sales. Since harvest takes place in the third and fourth quarters of the year, sales tend to be higher in these quarters. Nevertheless, CNOA’s recent sales are still considered quite large, compared with last year’s third quarter results of $22.4 million.

“I look forward to releasing more updates about China Organic shortly” said Mr. Li. “I will be detailing our vision for China Organic Agriculture in a strategic initiatives outline next week. Under my leadership I hope to mold CNOA into a purveyor of premium international food products, not only to our existing Chinese customers, but to the broader consumer market throughout Asia as well.”